---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-000056"
form_type: "8-K"
ticker: "SENS"
cik: "0001616543"
company_name: "Senseonics Holdings, Inc."
filed_at: "2026-01-02T23:59:59+00:00"
generated_at: "2026-05-16T11:48:54.876112+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Senseonics closes $1.1M acquisition of U.S. Eversense assets from Ascensia

## Summary
- U.S. asset purchase closed Jan 1, 2026; cash consideration ~$1.1M for inventory, licenses, and leases.
- European asset purchases (Italy, Germany, Spain, Sweden) expected to close by June 30, 2026, subject to local agreements.
- Amended collaboration agreement gives Senseonics 100% of European Eversense revenues from Jan 1; Ascensia's U.S. rights terminated.
- Director Koichiro Sato (PHC Holdings) resigned from board effective Dec 31, 2025; PHC retains designation right but won't currently exercise.

## SEC filing metadata
- accession: 0001104659-26-000056
- form_type: 8-K
- ticker: SENS
- cik: 0001616543
- company_name: Senseonics Holdings, Inc.
- filed_at: 2026-01-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1616543/000110465926000056/0001104659-26-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1616543/000110465926000056/tm261636d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-000056
- JSON: https://secwatch.observer/filing/0001104659-26-000056.json
- Plain text: https://secwatch.observer/filing/0001104659-26-000056.txt

## Key facts
- Material Agreements
  Senseonics Holdings, Inc. amended Amended and Restated Collaboration and Commercialization Agreement with Ascensia Diabetes Care Holdings AG (effective 2025-12-31).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: Ascensia Diabetes Care Holdings AG
  - Effective: 2025-12-31
  source text: In connection with entering into the Master Asset Purchase Agreement, Senseonics Inc. and the Seller entered into an Amended and Restated Collaboration and Commercialization Agreement (the “ A&R Collaboration Agreement ”) on the Execution Date, which amended and restated that certain Collaboration and Commercialization Agreement, dated August 9, 2020, between Senseonics Inc. and the Seller, as amended to date (the “ Existing Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1616543/000110465926000056/0001104659-26-000056-index.htm
- Material Agreements
  Senseonics Holdings, Inc. entered into Master Asset Purchase Agreement with Ascensia Diabetes Care Holdings AG valued at approximately $1.1 million (effective 2025-12-31).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Ascensia Diabetes Care Holdings AG
  - Value: approximately $1.1 million
  - Effective: 2025-12-31
  source text: On December 31, 2025 (the “ Execution Date ”), Senseonics Holdings, Inc. (the “ Company ”), Senseonics, Incorporated, a wholly-owned subsidiary of the Company (“ Senseonics Inc. ” and together with the Company, the “ Purchaser Parties ”) and Ascensia Diabetes Care Holdings AG (the “ Seller ”) entered into a master asset purchase agreement (the “ Master Asset Purchase Agreement ”), pursuant to which, among other things, the Purchaser Parties agreed to acquire Seller’s and as applicable, Seller’s affiliates’, right, title and interest in and to certain assets related Seller’s marketing, selling and distribution of the Eversense® product in the United States
  evidence_url: https://www.sec.gov/Archives/edgar/data/1616543/000110465926000056/0001104659-26-000056-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.